AstraZeneca’s Imfinzi shows event-free survival benefit in lung cancer patients in trial
Roland Magnusson/iStock Editorial by way of Getty Photographs AstraZeneca (NASDAQ:AZN) stated information from a section 3 trial confirmed that Imfinzi-based ...